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256Background: Paraplegia remains a devastating complication for patients undergoing thoracic aortic procedures.
Although surgical adjuncts have evolved to reduce the risk of paraplegia, no pharmacologic therapies have
proven efficacious in attenuating spinal cord ischemia–reperfusion injury. Effects of erythropoietin in spinal
cord ischemia–reperfusion injury, however, have not yet been elucidated. We hypothesized that pretreatment
with erythropoietin would attenuate functional and cytoarchitectural spinal cord injury related to high-risk aortic
procedures.
Methods: Adult male mice were subjected to ischemia–reperfusion. Aortic arch and proximal left subclavian
arteries were clamped for 5 minutes; animals were observed for 48 hours. Neurologic scores of hind limb func-
tion were assessed every 12 hours. Experimental groups consisted of treatment with erythropoietin 4 hours be-
fore crossclamping (n ¼ 7), ischemic controls (n ¼ 7), and sham ischemia (operation without crossclamping,
n ¼ 6). Thoracolumbar sections of spinal cord were removed after 48 hours and preserved for cytoarchitectural
analysis.
Results:Mice pretreated with erythropoietin exhibited significant preservation of hind limb motor function. All
mice without pretreatment were paralyzed at 48 hours. Mice with erythropoietin pretreatment had improved
motor function; 3 had no measurable neurologic deficit at 48 hours. Histologic analysis in mice treated with
erythropoietin showed markedly reduced neuronal cell injury.
Conclusions: Erythropoeitin preserves both function and histologic appearance in mice undergoing spinal cord
ischemia–reperfusion. With further elucidation of mechanisms of protection and optimal administration, eryth-
ropoietin could become an important adjunct in reducing the incidence and severity of spinal cord injury related
to aortic interventions. (J Thorac Cardiovasc Surg 2011;141:256-60)Spinal cord ischemia–reperfusion injury remains a signifi-
cant complication of thoracic aortic surgery. Lumbar drains,
intercostal artery reimplantation, left heart bypass, and hy-
pothermic circulatory arrest have all decreased rates of
paraplegia and paraparesis after aortic surgery. No pharma-
cologic adjuncts, however, have proven efficacious in atten-
uating the metabolic or inflammatory insult to the spinal
cord resulting from this ischemia–reperfusion injury.
Erythropoeitin, a 34-kDa endogenous glycoprotein, is
most widely recognized for its role in hematopoiesis. Eryth-
ropoietin is known to be upregulated in many tissues in
times of hypoxic stress as a result of stabilization of
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The Journal of Thoracic and Cardiovascular Surgerythropoeitin expression.1 This upregulation of erythro-
poeitin causes predictable effects in hematopoietic tissues
but appears to have cytoprotective effects independent of
this activity.2 In the brain and spinal cord, this beneficial ef-
fect has been seen in animal models in which erythropoietin
provides neuroprotection against many disease states, in-
cluding cerebral ischemia–reperfusion.3 Specifically in an-
imal stroke models, meta-analysis reveals a neuroprotective
effect of erythropoeitin with smaller infarct sizes and im-
proved functional outcomes after treatment.4
The mechanism of this neuroprotective effect has not
been well elucidated in either the brain or the spinal cord.
It is known that this effect is independent of the obvious
hematopoietic effects of erythropoeitin5 and that erythro-
poeitin is beneficial in other solid organ systems after ische-
mia–reperfusion injury. This mechanism may involve
erythropoeitin’s positive feedback on HIF1a expression,
because this protein is increased after renal ischemia–
reperfusion with erythropoietin pretreatment.6 Upregula-
tion of HIF1a has been implicated in neuroprotection after
mild to moderate cerebral ischemia7 but has never been
directly studied in the spinal cord.
From these data, we hypothesized that erythropoeitin
would have a neuroprotective effect on both functionalery c January 2011
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Smith et al Evolving Technology/Basic Scienceoutcomes and histologic appearance after ischemia–reper-
fusion of the spinal cord, an effect that might be due to mod-
ulation of HIF1a expression. The purposes of this study
were to evaluate the efficacy of erythropoietin in neuropro-
tection of the spinal cord after ischemia–reperfusion in
amurinemodel and to attempt to elucidate a neuroprotective
mechanism.FIGURE 1. Hind limb motor function after spinal cord ischemia–reperfu-
sion (IR) or sham ischemia: 9 represents perfect function, whereas 0 repre-
sents no function. Mice receiving erythropoietin pretreatment (epo)
showed significant improvement in function at all time points. Asterisk in-
dicates P<.05 by analysis of variance.
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Animals and Surgical Procedures
The Animal Care and Use Committee at the University of Colorado at
Denver Health Sciences Center approved all experiments, and this investi-
gation conformed to the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (www.nap.edu/catalog/5140.
html). C57bl/6 male mice were obtained from Jackson Laboratory (The
Jackson Laboratory, Bar Harbor, Me). Mice between 12 and 20 weeks old
were used for experimentation. With 2% isoflurane anesthesia,
a cervicothoracic approach was used to expose the aortic arch, as
previously described.8,9 The aortic arch was crossclamped between the
left common carotid artery and the left subclavian artery under direct
visualization. Ischemia continued for 5 minutes, after which clamps were
removed. An additional clamp was placed on the left subclavian artery.
Disruption of distal aortic flow was confirmed with a laser Doppler blood
flow monitor (Moor Instruments Ltd, Axminster, UK) to achieve a greater
than 90% decrease in distal aortic flow measured at the femoral artery.
An intraperitoneal dose of 400 IU/kg of heparin was administered to all
animals immediately before the procedure. Animals in the treatment
group received a 12-mg/kg dose of mouse recombinant erythropoietin
(Sigma-Aldrich Co, St Louis, Mo) intraperitoneally 4 hours before
operation. Sham ischemia mice had the aortic arch exposed through the
same procedure, but without aortic crossclamping. Animals that did not
receive erythropoietin pretreatment instead received placebo injections of
normal saline solution. Animals were humanely killed at 50 hours after
reperfusion, and their spinal cords were removed for analysis.
Functional Locomotor Scores
The Basso Mouse Scale for locomotion was used to quantify hind limb
function in mice after ischemia, which ranges from a score of 0 for com-
plete paraplegia to a score of 9 for normal function.10 Function was scored
at 12, 24, 36, and 48 hours after reperfusion.
Histologic Analysis
T-10 through L-3 spinal cord sections were harvested and preserved in
10% formalin for at least 24 hours before paraffin embedding, sectioning,
and hemotoxylin and eosin staining. Sections were analyzed for the number
of viable neurons.
Western Blot Analysis
Spinal cord specimens were preserved by flash freezing at80C. Spec-
imens were then homogenized in ethylenediaminetetraacetic acid–free
complete lysis–M buffer (Roche Diagnostics, Indianapolis, Ind), and pro-
tein quantification was performed with a Bradford Assay kit (Thermo
Fisher Scientific Inc, Rockford, Ill.). Standard quantities of protein wereThe Journal of Thoracic and Caloaded onto a 4% to 20% tris(hydroxymethyl)aminomethane (Tris) hydro-
chloride gradient gel (Bio-Rad Laboratories, Inc, Hercules, Calif), and
membranes were run in Tris-glycine running buffer. Protein from gels
was then transferred to a nitrocellulose membrane and blocked in 5%
nonfat milk for 1 hour. The membrane was then incubated in 1:500 mouse
anti–human HIF1a primary antibody overnight at 4C. After primary
incubation, membranes were washed 3 times for 5 minutes each in Tris-
buffered saline solution. Membranes were then incubated at room temper-
ature in 1:5000 horseradish peroxidase–linked secondary antibodies for
1 hour. Membranes were then rinsed with Tris-buffered saline solution,
and target bands were developed with enhanced chemiluminescence and
exposed on film. Densitometry was performed on all samples with ImageJ
software (National Institutes of Health, Bethesda, Md).
Statistics
Statistics were performed with analysis of variance with a Fisher post
hoc analysis for functional scores. Functional scores after ischemia–reper-
fusion were compared at all time points. Densitometry data was analyzed
with the Student t test.RESULTS
Mice recovering from anesthesia had initial functional
deficits, but mice in the treatment group (n ¼ 7) regained
significant function relative to those with no treatment
(n ¼ 7). During the next 48 hours, this improvement re-
mained in the treatment group. Sham ischemia mice
(n ¼ 6) had no decline in function at any time point studied
(Figure 1). Overall, all mice without treatment had perma-
nent paraplegia. In contrast, 43% of mice with erythropoei-
tin pretreatment regained full function. This effect was
observed indefinitely in animals observed longer than 48
hours (data not presented).
Spinal cord sections showed decreased neuron viability
after ischemia and reperfusion with no erythropoietin pre-
treatment (Figure 2). Qualitatively, sham ischemia micerdiovascular Surgery c Volume 141, Number 1 257
FIGURE 2. Hematoxylin and eosin staining of T9 to L3 spinal cord sections after 50 hours of reperfusion. Anterior horn cells are shown, with increased
neuron viability in control (Sham) and erythropoietin-pretreated (IRþEPO) groups relative to group with untreated ischemia–reperfusion (IR).
FIGURE 3. Densitometric analysis of hypoxia-inducible factor 1a (HIF)
immunoblotting showing no significant difference in protein expression
among sham ischemia (Normal), unmediated ischemia–reperfusion (IR),
and erythropoietin-treated (IRþEpo) groups. A.U., Arbitrary units.
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ron viability. Mice subjected to ischemia–reperfusion, in-
cluding erythropoeitin-treated mice, had increased
vacuolization relative to sham ischemia mice. Neurons in
the erythropoietin-treated group, however, had decreased
retraction of the nuclei and preservation of nuclear struc-
tures, including the nucleolus, indicating increased viabil-
ity. In addition, inflammatory cells were increased in the
ischemia–reperfusion group relative to both sham ischemia
and erythropoietin-treated groups.
HIF1a was detectable in normal (sham ischemia),
treated, and untreated spinal cords. No difference in level
of protein expression was detectable at 48 hours of reperfu-
sion (Figure 3).
DISCUSSION
This study demonstrates the potential of erythropoietin as
a pharmacologic adjunct to prevent spinal cord injury after
aortic surgery. Erythropoietin has shown promise previ-
ously in brain protection after various types of insults.5,11,12
This has been validated not only through animal models but
also in human trials. Beneficial effects are seen in diseases
ranging from amyotrophic lateral sclerosis to subarachnoid
hemorrhage. In the case of aneurysmal subarachnoid
hemorrhage in human beings, erythropoietin treatment
decreased delayed ischemic deficits after new ischemic
events from 40.0% to 7.5%.11 Although decreased vaso-
spasm seems to be attributable to the protective effect in
this study, the mechanisms by which this neuroprotection
occurs in general is not known. Educated speculation attri-258 The Journal of Thoracic and Cardiovascular Surgbutes this effect to the broad categories of antiapoptotic,
anti-inflammation, neurogenesis, and anti–oxidative stress
mechanisms.13
Little is known about the mechanisms of neuroprotection
of erythropoietin in the brain, and even less is known about
the mechanisms by which neuroprotection occurs in the spi-
nal cord. The same antiapoptotic, anti-inflammatory, neuro-
genic, and anti–oxidative stress mechanisms as in the brain
have been proposed by several authors, but the evidence for
these mechanisms is less substantial in the spinal cord.13
Rabbit and rat models of spinal cord ischemia–reperfusion
have suggested a beneficial role of erythropoietin; again,ery c January 2011
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These models showed significant injury attenuation for
dense, immediate paraplegia; however, the delayed,
progressive injuries from this study were not addressed.
In addition to providing a model for the study of progres-
sive neurologic injury, this murine model provides several
advantages. Most importantly, this model allows for genetic
manipulations of mice, which will facilitate further elucida-
tion of the molecular mechanisms behind our findings. The
short ischemic time required to produce an injury, attribut-
able to the high metabolic rate in the mouse, allows faster
experimentation at lower costs. In addition, the spinal
cord vasculature in the mouse is more similar to that of a hu-
man than are other well-established animal models.8
These data demonstrate that erythropoietin pretreatment
in a mouse model of spinal cord ischemia and reperfusion is
beneficial in reducing both immediate and delayed neuro-
logic injury. Unlike in previous reports, control mice in
this series showed an initial injury that progressed to dense
paraplegia by 48 hours. In contrast, erythropoietin-
pretreated mice showed improvement in both initial injury
and delayed-onset paraparesis and paraplegia. All mice
that underwent ischemia and reperfusion in our model had
complete paraplegia develop without erythropoietin pre-
treatment. A significant number of mice with pretreatment
recovered full neurologic function. These observations
alone merit further investigation into the mechanisms and
clinical applications of erythropoeitin treatment.
Wewere not able to observe a difference in HIF1a protein
expression at the 48 hour time point. This finding does not,
however, exclude the possibility of this protein’s involve-
ment in neuroprotective mechanisms. Models of renal is-
chemia and reperfusion have shown increased expression
of HIF1a at 24 and 72 hours after ischemia–reperfusion in
human cell lines. In light of the vast differences in metabolic
rates between mice and human beings, however as well as
inherent differences between in vitro and in vivo experi-
ments, differential HIF1a expressions may be observable
at shorter intervals after reperfusion in our model.6
The immediate and delayed injuries seen after spinal cord
ischemia–reperfusion can be explained by breaking down
the mechanism into 2 components. The initial injury may
be caused by a metabolic (or ischemic) insult to the spinal
cord, whereas the progressive injury may be attributable
to the metabolic insult combined with a secondary inflam-
matory response. Inferring mechanistic implications from
our data on the basis of this 2-component model of injury
is speculative but not unsupported by the literature. This in-
jury in the brain has been hypothesized to be due to early
injury secondary to resident inflammatory cells (mainly mi-
croglia), with a secondary response caused by recruited in-
flammatory mediators and proinflammatory cells.16 Of
note, erythropoeitin derivatives have been known to protect
tissue whether delivered before or after injury.17 TheseThe Journal of Thoracic and Cafindings imply that erythropoeitin may act to attenuate
both ischemic insult and reperfusion injury.
Erythropoietin pretreatment for patients undergoing tho-
racic aortic surgery is easily applied. The potential thrombo-
sis issue may be negated by the requisite heparinization.
Moreover, thrombosis occurs in patients with hematocrits
greater than 40%, which is clearly not an issue after these
procedures. In fact, the hematopoietic effect of erythropoei-
tin may actually decrease the need for transfusion in the
postoperative period.Many potential side effects of erythro-
poietin may actually prove beneficial in this setting.
Although our results are promising, they are not without
limitations. A recent double-blind, placebo-controlled trial
showed increased mortality and no advantageous effects in
patients treated with erythropoietin in acute ischemic
stroke.18 Although this finding does hamper enthusiasm
for treating spinal cord ischemia–reperfusion injury with
erythropoietin, the mechanisms of injury and patient condi-
tions in these clinical scenarios are significantly different
and provide no reason to believe that this same effect would
become evident in aortic surgical patients, given the 20 year
safety record of this drug. Our small sample size also limits
the applicability of this study, although larger sample sizes
can easily be produced to overcome this dilemma. The alti-
tude at which our center is located may also make results
difficult to reproduce at lower elevations; however, the over-
all mechanistic implications are still applicable.
In summary, this study provides evidence that erythropoi-
etin may affect both the ischemic and reperfusion injuries
related to thoracic aortic surgery. Further, study regarding
the mechanisms of neuroprotection by erythropoietin may
lead to direct benefit for patients while expanding our un-
derstanding of spinal cord ischemia–reperfusion injury.References
1. Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxia-inducible factors (HIF),
HIF hydroxylases and oxygen sensing. Cell Mol Life Sci. 2009;66:3539-54.
2. Joyeux-Faure M. Cellular protection by erythropoietin: new therapeutic implica-
tions? J Pharmacol Exp Ther. 2007;323:759-62.
3. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its
potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol.
2006;18:132-8.
4. Minnerup J, Heidrich J, Rogalewski A, Sch€abitz WR, Wellmann J. The efficacy
of erythropoietin and its analogues in animal stroke models: a meta-analysis.
Stroke. 2009;40:3113-20.
5. Wang Y, Zhang ZG, Rhodes K, Renzi M, Zhang RL, Kapke A, et al. Post-ische-
mic treatment with erythropoietin or carbamylated erythropoietin reduces infarc-
tion and improves neurological outcome in a rat model of focal cerebral
ischemia. Br J Pharmacol. 2007;151:1377-84.
6. Imamura R, Moriyama T, Isaka Y, Namba Y, Ichimaru N, Takahara S, et al.
Erythropoietin protects the kidneys against ischemia reperfusion injury by acti-
vating hypoxia inducible factor-1a. Transplantation. 2007;83:1371-9.
7. Shi H. Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke. Curr
Med Chem. 2009;16:4593-600.
8. Lang-Lazdunski L, Matsushita K, Hirt L, Waeber C, Vonsattel JP,
Moskowitz MA, et al. Spinal cord ischemia. Development of a model in the
mouse. Stroke. 2000;31:208-13.
9. Stone DH, Conrad MF, Albadawi H, Entabi F, Stoner MC, Cambria RP, et al. Ef-
fect of PJ34 on spinal cord tissue viability and gene expression in a murine model
of thoracic aortic reperfusion injury. Vasc Endovascular Surg. 2009;43:444-51.rdiovascular Surgery c Volume 141, Number 1 259
Evolving Technology/Basic Science Smith et al
E
T
/B
S10. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG.
Basso Mouse Scale for locomotion detects differences in recovery after spinal
cord injury in five common mouse strains. J Neurotrauma. 2006;23:635-59.
11. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN,
et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits
following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-
blind, placebo-controlled trial. Clinical article. J Neurosurg. 2009;111:171-80.
12. Talving P, Lustenberger T, Kobayashi L, Inaba K, Barmparas G, Schn€uriger B,
et al. Erythropoiesis stimulating agent administration improves survival after se-
vere traumatic brain injury: amatched case control study.Ann Surg. 2010;251:1-4.
13. Byts N, Siren AL. Erythropoietin: a multimodal neuroprotective agent. Exp
Transl Stroke Med. 2009;21;1:4.
14. S€onmez A, Kabakc¸i B, Vardar E, G€urel D, S€onmez U, Orhan YT, et al. Erythro-
poietin attenuates neuronal injury and potentiates the expression of pCREB in an-
terior horn after transient spinal cord ischemia in rats. Surg Neurol. 2007;68:
297-303.
15. Celik M, G€okmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al.
Erythropoietin prevents motor neuron apoptosis and neurologic disability in ex-
perimental spinal cord ischemic injury. Proc Natl Acad Sci U S A. 2002;99:
2258-63.
16. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of in-
flammatory cells. J Leukoc Biol. 2010;87:779-89.
17. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M. Derivatives of eryth-
ropoietin that are tissue protective but not erythropoietic. Science. 2004;305:
239-42.
18. Ehrenreich H,Weissenborn K, Prange H, Schneider D,Weimar C,Wartenberg K,
et al. Recombinant human erythropoietin in the treatment of acute ischemic
stroke. Stroke. 2009;40:e647-56.Discussion
Dr John S. Ikonomidis (Charleston, SC).Drs Burdon and Full-
erton, I have no relationships to disclose with regard to this discus-
sion. I thank Ross Bremner and the Western Thoracic Surgical
Association for the opportunity to discuss this presentation today,
and I rise to congratulate Drs Smith and Reece and the University
of Colorado group for a really compelling characterization of this
novel and interesting spinal cord protection phenomenon that we
are really just starting to understand.
Dr Smith, I have a couple of comments and questions. I would
like you to answer each question as I give it.
First, at first glance at this data, I am astounded that 5 minutes of
normothermic ischemia caused uniformparalysis in every untreated
animal studied. This is a devastating amount of damage that cer-
tainly would not be expected to occur in a similar clinical scenario
in human beings, so I wonder whether you could comment on any
potential anatomic or vascular-related differences between the mu-
rine model and human anatomy that could impede the extrapolation
of these results to human patients into the clinical setting.
Dr Smith. Absolutely. Thank you for your kind comments. We
feel that the most important thing is that the functional injury that
we observe after aortic occlusion is very similar to what is seen
clinically in human patients. The spinal cord anatomy and vascu-
lature of a mouse is actually very similar to those of human beings,
more than other animal models that have been used. Finally, the
metabolic rate of a mouse is so much faster than that of a human
being that you might actually expect that very short ischemic times
such as those we used to have a much more pronounced effect.
Dr Ikonomidis. Thank you. Some logistic issues related to
erythropoietin. How did you arrive at the timing and dosage of
erythropoietin used in this study?
Dr Smith. We looked at the other literature, on the brain, and
there have beenmany studies of the brain that outline different tim-260 The Journal of Thoracic and Cardiovascular Surging of administration and dosing, and we chose from there. In ad-
dition, we do not know the optimal timing or dosage, and we are
doing further studies now to try to figure that out.
Dr Ikonomidis.Howmuch does this cost in a mouse, and if you
were to extrapolate that dose to human beings, how much would it
cost if we were to use this clinically?
Dr Smith. I have not broken down the cost for a mouse. If you
extrapolate the dose we used to a human dose, it would be about
120 unit/kg, so that would be about $200 to $300 per dose.
Dr Ikonomidis. It occurs to me that a single dose of erythropoi-
etin, given the timing of this study, probably would not cause sig-
nificant hematopoietic effects and is probably pretty benign. So in
light of what we know already about it, should we start doing this
in every case every time we do a descending thoracic replacement
or thoracoabdominal? What is the harm in not giving it?
Dr Smith. I think that we need to further elucidate the mecha-
nisms before we move into human trials, but because of the safety
profile of erythropoietin and in the general population much less
the aortic surgical population, I think it is very promising for treat-
ing every patient in the future.
Dr Ikonomidis. Your answer to that question is a good segue to
the next one. There is relatively little literature on this subject, but
the literature that is available shows this effect quite uniformly, so I
think that it is reasonable to say that it really exists, and I think it is
time to move forward and really start hammering out mechanisms.
Your HIF1a data were not particularly compelling, but there are
a variety of other potential mechanisms. These include anti-in-
flammatory effects, anti-apoptotic effects, modulation of oxidative
stress, neurohormonal modulation of vascular tone, and even in-
creased phosphorylation of certain upstream protective transcrip-
tion factors, such as CREB. Are you leaning toward any of these
particular mechanisms, or do you have a different mechanism in
mind? How do you plan to study that?
Dr Smith. As you mentioned, there are several possible mech-
anisms that may be responsible for this effect. Although we did not
observe a change in HIF1a at 48 hours, we still believe that it may
be responsible, so we would like to look at and are looking at dif-
ferent time points to see whether we can show different expression
after erythropoietin administration.
With respect to other mechanisms that may be involved, we are
also looking at cytokine expression as a function of time after is-
chemia and reperfusion to see whether we can determine the im-
portant proinflammatory and anti-inflammatory cytokines that
are responsible for the injury. Also, as I mentioned briefly, there
are erythropoietin derivatives that do not have any hematopoietic
effect but do have a cytoprotective effect, so we are using these
to try to tease out the actual neuroprotective effects of these drugs.
Dr Jeffrey Gaca (Durham, NC). We often do these operations
under hypothermia. Do you think that maybe you could reproduce
this experiment under hypothermia and get different results,
maybe even better results? A lot of times we don’t do them under
normothermia now.
Dr Smith. Absolutely, that is a great question. I think that if
we did these experiments under hypothermic conditions, we
might see even more neuroprotection. We do not know that for
sure, because we have only done this under normothermia, but
that would be a reasonable thing to try because that is what is
done clinically.ery c January 2011
